- Conditions
- Asthma
- Interventions
- GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
- Biological · Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,717 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 370
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- GW685698X, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 622 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 95
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more
- Conditions
- Opioid Abuse Nondependent
- Interventions
- PTI-821 capsule Manipulated, PTI-821 Non-manipulated, OxyContin, Placebo, Oxycodone
- Drug · Other
- Lead sponsor
- Pain Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Asthma
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Glendale, Arizona • San Jose, California + 18 more
- Conditions
- Schizophrenia
- Interventions
- Talnetant
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Anaheim, California • Cerritos, California + 17 more
- Conditions
- Parkinson's Disease (PD)
- Interventions
- ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 69
- States / cities
- Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more
- Conditions
- Parkinson's Disease
- Interventions
- Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Aliso Viejo, California • Irvine, California + 17 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol ), Placebo (QVA149)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 53
- States / cities
- Anaheim, California • Escondido, California • Riverside, California + 45 more
- Conditions
- Hormone Receptor Positive Breast Cancer
- Interventions
- faslodex 500mg, arimidex 1mg, faslodex dummy, arimidex dummy
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 12
- States / cities
- Modesto, California • Savannah, Georgia • Auburn, Maine + 9 more
- Conditions
- Major Depressive Disorder
- Interventions
- Placebo, Escitalopram, JNJ-18038683
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Glendale, California + 23 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- JTT-851, Glimepiride, Placebo for Active, Placebo for comparator
- Drug
- Lead sponsor
- Akros Pharma Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 76 more
- Conditions
- Asthma
- Interventions
- indacaterol maleate
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 5
- States / cities
- Denver, Colorado • North Dartmouth, Massachusetts • Minneapolis, Minnesota + 2 more
- Conditions
- Schizophrenia
- Interventions
- AZD2624, Olanzapine, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Qt Interval, Variation in
- Interventions
- WCK 2349, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- Wockhardt
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Asthma
- Interventions
- Vilanterol, Salmeterol Inhalation Powder, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder Diskus
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 11
- States / cities
- Huntington Beach, California • Orlando, Florida • Tallahassee, Florida + 8 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- PF-04457845, Naproxen
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 5
- States / cities
- Miami, Florida • Overland Park, Kansas • San Antonio, Texas
- Conditions
- Respiratory Depression
- Interventions
- Belbuca 300 µg, Belbuca 600 µg, Belbuca 900 µg, Oxycodone 30 mg, Oxycodone 60 mg, Placebo
- Drug
- Lead sponsor
- BioDelivery Sciences International
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Complicated Intra-abdominal Infections
- Interventions
- Eravacycline, Ertapenem, Placebo
- Drug
- Lead sponsor
- Tetraphase Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 19
- States / cities
- Florence, Alabama • Mobile, Alabama • Glendale, California + 16 more
- Conditions
- Healthy
- Interventions
- Lacosamide (LCM), Carbamazepine Immediate Release (CBZ-IR)
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Overland Park, Kansas
- Conditions
- Ulcerative Colitis
- Interventions
- UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Greenville, North Carolina • Salt Lake City, Utah
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Remibrutinib, Teriflunomide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Ozanimod, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 6
- States / cities
- Berkeley, California • Fresno, California • Sacramento, California + 3 more